Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Alnylam Pharmaceuticals |
37.04 Bn |
34.03 Bn |
959.66 Mn |
1,228.66% |
| Date | Value |
|---|
| Mar 31, 2026 |
1,228.66% |
| Dec 31, 2025 |
233.17% |
| Sep 30, 2025 |
362.33% |
| Jun 30, 2025 |
-292.43% |
| Mar 31, 2025 |
72.32% |
| Dec 31, 2024 |
39.24% |
| Sep 30, 2024 |
-175.51% |
| Jun 30, 2024 |
93.88% |
| Mar 31, 2024 |
62.13% |
| Dec 31, 2023 |
33.55% |
| Sep 30, 2023 |
136.40% |
| Jun 30, 2023 |
0.50% |
| Mar 31, 2023 |
27.56% |
| Dec 31, 2022 |
19.72% |
| Sep 30, 2022 |
-98.48% |
| Jun 30, 2022 |
-46.34% |
| Mar 31, 2022 |
-20.00% |
| Dec 31, 2021 |
-6.13% |
| Sep 30, 2021 |
19.26% |
| Jun 30, 2021 |
-5.76% |
